Search

Leading with science, grounded in patient impact: Meet James Richardson, M.D.
Community Letter: Safety Update regarding Elevidys in non-ambulatory individuals with Duchenne
Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label
Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 (Delandistrogene Moxeparvovec) in Participants With Duchenne Muscular Dystrophy (DMD) (EMBARK)
Grants & Giving
Community Letter: Sarepta Therapeutics Provides Statement on Shipments of ELEVIDYS
Community Letter: Update regarding ELEVIDYS
Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union